StockData
BioStem Technologies, Inc. logo

BioStem Technologies, Inc. (BSEM) shareholders

BSEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$0.64−0.07 (-10.23%)

Close on Nov 20, 2026Market cap $11.34MP/E –Yield –

Ownership

Who owns BioStem Technologies's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 1 sales
Net sold $14.30K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Andrew Van Vurst3,854,45218.40%13G (passive)Sep 30, 2026
Jason Matuszewski3,665,89917.40%13G (passive)Sep 30, 2026
The PNC Financial Services Group, Inc.1,941,39010.40%13G (passive)Oct 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jason MatuszewskiChief Executive Officer, Director, 10% owner1,539,2518.62%Nov 19, 2026
Vurst Andrew Smith-VanChief Operating Officer, Director, 10% owner1,789,80910.03%Oct 9, 2026
Brandon PoeChief Financial Officer60,7630.34%Nov 13, 2026
Michael A. FortunatoChief Accounting Officer69,6340.39%Nov 10, 2026
Barry HassettChief Commercial Officer5,2560.03%Nov 3, 2026
Katherine GorrellCLCO––Aug 14, 2026
Kenneth Howard Warrington JrDirector33,9280.19%Sep 17, 2026
Mark A. GlickmanDirector7,6710.04%Aug 28, 2026
Hannaway Rayna LesserDirector7,6710.04%Aug 28, 2026
Jodi UngrodtDirector11,2950.06%Aug 28, 2026
Steven D. SonenreichDirector7,6710.04%Aug 28, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jason Matuszewski
Chief Executive Officer, Director, 10% owner
Nov 17, 2026Sale−14,300$1.00$14.30K1,539,251
Brandon Poe
Chief Financial Officer
Nov 11, 2026Option exercise+2,699––60,763
Michael A. Fortunato
Chief Accounting Officer
Nov 9, 2026Option exercise+970––69,634
Barry Hassett
Chief Commercial Officer
Nov 1, 2026Option exercise+253––5,256
Vurst Andrew Smith-Van
Chief Operating Officer, Director, 10% owner
Oct 7, 2026Option exercise+250,000$2.00$500.00K1,789,809
Jason Matuszewski
Chief Executive Officer, Director, 10% owner
Oct 7, 2026Option exercise+250,000$2.00$500.00K1,553,551
Vurst Andrew Smith-Van
Chief Operating Officer, Director, 10% owner
Sep 17, 2026Option exercise+9,574––1,539,809
Jason Matuszewski
Chief Executive Officer, Director, 10% owner
Sep 17, 2026Option exercise+16,650––1,303,552
Kenneth Howard Warrington Jr
Director
Sep 15, 2026Option exercise+1,694––33,928
Brandon Poe
Chief Financial Officer
Sep 15, 2026Option exercise+1,694––58,062
Vurst Andrew Smith-Van
Chief Operating Officer, Director, 10% owner
Sep 15, 2026Option exercise+7,622––1,530,235
Michael A. Fortunato
Chief Accounting Officer
Sep 15, 2026Option exercise+4,234––68,664
Jason Matuszewski
Chief Executive Officer, Director, 10% owner
Sep 15, 2026Option exercise+8,469––1,286,902
Barry Hassett
Chief Commercial Officer
Sep 9, 2026Option exercise+500––5,003
Mark A. Glickman
Director
Aug 27, 2026Option exercise+7,671––7,671
Hannaway Rayna Lesser
Director
Aug 27, 2026Option exercise+7,671––7,671
Jodi Ungrodt
Director
Aug 27, 2026Option exercise+5,647––11,295
Steven D. Sonenreich
Director
Aug 27, 2026Option exercise+7,671––7,671
Kenneth Howard Warrington Jr
Director
Aug 27, 2026Option exercise+5,094––32,234
Brandon Poe
Chief Financial Officer
Aug 11, 2026Option exercise+10,634––56,368
Michael A. Fortunato
Chief Accounting Officer
Aug 9, 2026Option exercise+970––64,430

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
2.83%
0M shares short
Days to cover
1.5
At 0M shares a day
Change since last report
-14.0%
From 0M shares
Short volume, 20 days
60.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioStem Technologies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 11,995 shares on Oct 14, 2026 over the last 90 days.

See a number that looks wrong?